Tuesday, 18 Jun 2019

You are here

Despite Gout Numbers and Flares, Allopurinol is Underutilized

A population-based survey from South Australia shows that gout flares are common in the community and have a significant effect on health-related quality of life (HRQoL), yet there is significant undertreatment of gout, even in those on current allopurinol.

The South Australia Health Omnibus Survey is an annual, face-to-face adult population-based survey that collected information on self-reported medically diagnosed gout, allopurinol use and gout attacks (flares) in the prior 12 months.

Overall the findings showed:

  • the prevalence of gout in the population was 6.5%
  • 37.1% of gout patients were on current allopurinol and 23.2% reported prior use
  • frequent flares (≥ 2/year) were reported by 25% of gout
    • were more likely with: younger age, higher BMI, and current allopurinol use (p < 0.05)
    • in those with frequent gout flares, 51% were on current allopurinol therapy
  • gout flares were associated with a lower physical HRQoL (p = 0.012). 

Despite the prevalence, flares rates and HRQoL effects seen with gout, only 37% were on allopurinol (51% in those with frequent attacks).

Undertreated disease and suboptimal use of urate lowering therapy continue to plaque gout management in the populace.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Updated 2018 EULAR Recommendations for the Diagnosis of Gout

The first EULAR recommendations for the diagnosis of gout were published in 2006. A task force was formed and following a systematic review, they voted unanimously for changes in all items of the 2006 recommendations.

Excess Non-CV Mortality Persists in Gout

Patients with gout not only have a well-recognized increased risk of dying from cardiovascular (CV) disease, but also have higher all-cause mortality and die prematurely from other diseases, a Swedish study indicated.

Coexistent Gout Increases Risk in Rheumatoid Arthritis

It his often said that gout and rheumatoid arthritis (RA) cannot coexist and where confusion exists, a good history and testing for serum urate (SUA) and rheumatoid factor (RF) can usually clarify the dominant disorders. A recent study shows that hyperuricemia and gout are uncommon in RA, but when present shows an increased risk of comorbidities and cardiovascular (CV) mortality.

Less Structural Damage with T2T in Gout

A two‐year randomized clinical trial has demonstrated that allopurinol dose escalation to a target serum urate (SU) results in less bone erosion, structural damage and urate crystal deposition in patients with gout.

Ideal Outcomes are Seldom Achieved in Gout

Studies from a cohort of gout patients in Mexico shows that long-term goals of a target serum urate (sUA) < 6 mg/dL and remission are rare, especially for those with severe gout.